Published in J Infect Dis on May 24, 2004
Neuronal CXCL10 directs CD8+ T-cell recruitment and control of West Nile virus encephalitis. J Virol (2005) 3.31
Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatment. BMC Infect Dis (2005) 1.91
Antiretroviral treatment effect on immune activation reduces cerebrospinal fluid HIV-1 infection. J Acquir Immune Defic Syndr (2008) 1.46
HIV-1 neuroimmunity in the era of antiretroviral therapy. Neurobiol Dis (2010) 1.32
Compartmentalized human immunodeficiency virus type 1 present in cerebrospinal fluid is produced by short-lived cells. J Virol (2005) 1.22
Raltegravir treatment intensification does not alter cerebrospinal fluid HIV-1 infection or immunoactivation in subjects on suppressive therapy. J Infect Dis (2011) 1.15
Biocompatibility of solid-dosage forms of anti-human immunodeficiency virus type 1 microbicides with the human cervicovaginal mucosa modeled ex vivo. Antimicrob Agents Chemother (2006) 1.02
Enhancement of human immunodeficiency virus (HIV)-specific CD8+ T cells in cerebrospinal fluid compared to those in blood among antiretroviral therapy-naive HIV-positive subjects. J Virol (2008) 1.02
Cellular Composition of Cerebrospinal Fluid in HIV-1 Infected and Uninfected Subjects. PLoS One (2013) 0.96
Cerebrospinal fluid (CSF) CD8+ T-cells that express interferon-gamma contribute to HIV associated neurocognitive disorders (HAND). PLoS One (2015) 0.94
A hematopoietic contribution to microhemorrhage formation during antiviral CD8 T cell-initiated blood-brain barrier disruption. J Neuroinflammation (2012) 0.94
Pro-inflammatory functions of astrocytes correlate with viral clearance and strain-dependent protection from TMEV-induced demyelinating disease. Virology (2008) 0.92
Role of the immune system in HIV-associated neuroinflammation and neurocognitive implications. Brain Behav Immun (2014) 0.92
Decreased CXCR3+ CD8 T cells in advanced human immunodeficiency virus infection suggest that a homing defect contributes to cytotoxic T-lymphocyte dysfunction. J Virol (2007) 0.91
Evolving character of chronic central nervous system HIV infection. Semin Neurol (2014) 0.89
Minocycline fails to modulate cerebrospinal fluid HIV infection or immune activation in chronic untreated HIV-1 infection: results of a pilot study. AIDS Res Ther (2011) 0.86
Programming of neurotoxic cofactor CXCL-10 in HIV-1-associated dementia: abrogation of CXCL-10-induced neuro-glial toxicity in vitro by PKC activator. J Neuroinflammation (2012) 0.86
CCR5 blockade for neuroinflammatory diseases - beyond control of HIV. Nat Rev Neurol (2016) 0.83
Regulation of immune response and inflammatory reactions against viral infection by VCAM-1. J Virol (2008) 0.82
Peripheral neuropathy in primary HIV infection associates with systemic and central nervous system immune activation. J Acquir Immune Defic Syndr (2014) 0.80
Migration of CD8+ T Cells into the Central Nervous System Gives Rise to Highly Potent Anti-HIV CD4dimCD8bright T Cells in a Wnt Signaling-Dependent Manner. J Immunol (2015) 0.79
Morphine induces splenocyte trafficking into the CNS. J Neuroimmune Pharmacol (2011) 0.78
Transmigration of macrophages across the choroid plexus epithelium in response to the feline immunodeficiency virus. Cell Tissue Res (2012) 0.77
Trypanosoma cruzi (Chagas' disease agent) reduces HIV-1 replication in human placenta. Retrovirology (2008) 0.76
Immune Activation and HIV-Specific CD8(+) T Cells in Cerebrospinal Fluid of HIV Controllers and Noncontrollers. AIDS Res Hum Retroviruses (2016) 0.76
Prevalence and Correlates of Persistent HIV-1 RNA in Cerebrospinal Fluid During Antiretroviral Therapy. J Infect Dis (2016) 0.75
Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J Exp Med (2008) 5.94
Maternal alloantigens promote the development of tolerogenic fetal regulatory T cells in utero. Science (2008) 5.76
Human CD4+ CD25+ regulatory T cells control T-cell responses to human immunodeficiency virus and cytomegalovirus antigens. J Virol (2004) 3.58
Expansion of a unique CD57⁺NKG2Chi natural killer cell subset during acute human cytomegalovirus infection. Proc Natl Acad Sci U S A (2011) 3.53
HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment. J Infect Dis (2010) 3.46
CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16+ NK-cell subset. Blood (2010) 3.32
Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia. J Infect Dis (2006) 2.74
Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin patient. PLoS Pathog (2013) 2.44
Functionally distinct subsets of human NK cells and monocyte/DC-like cells identified by coexpression of CD56, CD7, and CD4. Blood (2009) 2.43
Treatment benefit on cerebrospinal fluid HIV-1 levels in the setting of systemic virological suppression and failure. J Infect Dis (2006) 2.36
Optimization of methods to assess human mucosal T-cell responses to HIV infection. J Immunol Methods (2003) 2.32
Comparison of the ELISPOT and cytokine flow cytometry assays for the enumeration of antigen-specific T cells. J Immunol Methods (2003) 2.28
Tregs control the development of symptomatic West Nile virus infection in humans and mice. J Clin Invest (2009) 2.18
Phenotype switching by inflammation-inducing polarized Th17 cells, but not by Th1 cells. J Immunol (2008) 2.09
Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection. AIDS Res Ther (2010) 1.99
HIV-related neuropathology, 1985 to 1999: rising prevalence of HIV encephalopathy in the era of highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2002) 1.94
Immune activation of the central nervous system is still present after >4 years of effective highly active antiretroviral therapy. J Infect Dis (2007) 1.92
Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatment. BMC Infect Dis (2005) 1.91
Cutting Edge: KIR3DS1, a gene implicated in resistance to progression to AIDS, encodes a DAP12-associated receptor expressed on NK cells that triggers NK cell activation. J Immunol (2007) 1.87
Progressive multifocal leukoencephalopathy in HIV-1 infection. Lancet Infect Dis (2009) 1.82
Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity. Blood (2012) 1.81
Regulation of T cell responses in the developing human fetus. J Immunol (2006) 1.78
Development of diagnostic criteria for serious non-AIDS events in HIV clinical trials. HIV Clin Trials (2010) 1.75
Immunologic and virologic evolution during periods of intermittent and persistent low-level viremia. AIDS (2004) 1.75
Selective loss of innate CD4(+) V alpha 24 natural killer T cells in human immunodeficiency virus infection. J Virol (2002) 1.74
Strong HIV-1-specific T cell responses in HIV-1-exposed uninfected infants and neonates revealed after regulatory T cell removal. PLoS One (2006) 1.73
Trafficking of human immunodeficiency virus type 1-specific CD8+ T cells to gut-associated lymphoid tissue during chronic infection. J Virol (2003) 1.71
Compartmentalization and clonal amplification of HIV-1 variants in the cerebrospinal fluid during primary infection. J Virol (2009) 1.70
T cell responses to human endogenous retroviruses in HIV-1 infection. PLoS Pathog (2007) 1.70
Compartmentalized human immunodeficiency virus type 1 originates from long-lived cells in some subjects with HIV-1-associated dementia. PLoS Pathog (2009) 1.66
Seroreversion in subjects receiving antiretroviral therapy during acute/early HIV infection. Clin Infect Dis (2006) 1.65
Determination of the underlying cause of death in three multicenter international HIV clinical trials. HIV Clin Trials (2008) 1.65
Central nervous system immune activation characterizes primary human immunodeficiency virus 1 infection even in participants with minimal cerebrospinal fluid viral burden. J Infect Dis (2011) 1.59
Highly effective control of an AIDS virus challenge in macaques by using vesicular stomatitis virus and modified vaccinia virus Ankara vaccine vectors in a single-boost protocol. J Virol (2004) 1.58
The definition of HIV-associated neurocognitive disorders: are we overestimating the real prevalence? BMC Infect Dis (2011) 1.54
Rapid progressing allele HLA-B35 Px restricted anti-HIV-1 CD8+ T cells recognize vestigial CTL epitopes. PLoS One (2010) 1.49
Cerebrospinal fluid interferon-gamma-inducible protein 10 (IP-10, CXCL10) in HIV-1 infection. J Neuroimmunol (2005) 1.49
FOXP3 expressing CD127lo CD4+ T cells inversely correlate with CD38+ CD8+ T cell activation levels in primary HIV-1 infection. J Leukoc Biol (2007) 1.47
Persistent intrathecal immune activation in HIV-1-infected individuals on antiretroviral therapy. J Acquir Immune Defic Syndr (2008) 1.47
Conferral of enhanced natural killer cell function by KIR3DS1 in early human immunodeficiency virus type 1 infection. J Virol (2008) 1.47
Human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T(EMRA) cells in early infection are linked to control of HIV-1 viremia and predict the subsequent viral load set point. J Virol (2007) 1.46
Abundant expression of granzyme A, but not perforin, in granules of CD8+ T cells in GALT: implications for immune control of HIV-1 infection. J Immunol (2004) 1.46
Antiretroviral treatment effect on immune activation reduces cerebrospinal fluid HIV-1 infection. J Acquir Immune Defic Syndr (2008) 1.46
HIV-1 replication in the central nervous system occurs in two distinct cell types. PLoS Pathog (2011) 1.45
Cerebrospinal fluid and neuroimaging biomarker abnormalities suggest early neurological injury in a subset of individuals during primary HIV infection. J Infect Dis (2013) 1.42
Nine-color flow cytometry for accurate measurement of T cell subsets and cytokine responses. Part I: Panel design by an empiric approach. Cytometry A (2008) 1.40
Cross-sectional characterization of HIV-1 env compartmentalization in cerebrospinal fluid over the full disease course. AIDS (2009) 1.40
Elevated cerebrospinal fluid neurofilament light protein concentrations predict the development of AIDS dementia complex. J Infect Dis (2007) 1.36
Undetectable cerebrospinal fluid HIV RNA and beta-2 microglobulin do not indicate inactive AIDS dementia complex in highly active antiretroviral therapy-treated patients. J Acquir Immune Defic Syndr (2005) 1.32
Amyloid and tau cerebrospinal fluid biomarkers in HIV infection. BMC Neurol (2009) 1.32
CD56negCD16⁺ NK cells are activated mature NK cells with impaired effector function during HIV-1 infection. Retrovirology (2013) 1.30
Sequential broadening of CTL responses in early HIV-1 infection is associated with viral escape. PLoS One (2007) 1.30
Cerebrospinal fluid HIV-1 infection usually responds well to antiretroviral treatment. Antivir Ther (2005) 1.28
Amplification of low-frequency antiviral CD8 T cell responses using autologous dendritic cells. AIDS (2002) 1.27
Broadly immunogenic HLA class I supertype-restricted elite CTL epitopes recognized in a diverse population infected with different HIV-1 subtypes. J Immunol (2008) 1.25
HIV-specific CD8+ T cell function in children with vertically acquired HIV-1 infection is critically influenced by age and the state of the CD4+ T cell compartment. J Immunol (2003) 1.25
Defining and evaluating HIV-related neurodegenerative disease and its treatment targets: a combinatorial approach to use of cerebrospinal fluid molecular biomarkers. J Neuroimmune Pharmacol (2006) 1.24
Expression profile of host restriction factors in HIV-1 elite controllers. Retrovirology (2013) 1.24
T cell immunity in acute HIV-1 infection. J Infect Dis (2010) 1.22
CSF neurofilament protein (NFL) -- a marker of active HIV-related neurodegeneration. J Neurol (2007) 1.22
Development of innate CD4+ alpha-chain variable gene segment 24 (Valpha24) natural killer T cells in the early human fetal thymus is regulated by IL-7. Proc Natl Acad Sci U S A (2004) 1.21
Unlike Th1, Th17 cells mediate sustained autoimmune inflammation and are highly resistant to restimulation-induced cell death. J Immunol (2009) 1.19
Dual pressure from antiretroviral therapy and cell-mediated immune response on the human immunodeficiency virus type 1 protease gene. J Virol (2003) 1.19
Strong human endogenous retrovirus-specific T cell responses are associated with control of HIV-1 in chronic infection. J Virol (2011) 1.19
Is it time to rethink how neuropsychological tests are used to diagnose mild forms of HIV-associated neurocognitive disorders? Impact of false-positive rates on prevalence and power. Neuroepidemiology (2013) 1.17
Raltegravir treatment intensification does not alter cerebrospinal fluid HIV-1 infection or immunoactivation in subjects on suppressive therapy. J Infect Dis (2011) 1.15
Suppression of HIV-1 plasma viral load below detection preserves IL-17 producing T cells in HIV-1 infection. AIDS (2008) 1.14
HERV-K-specific T cells eliminate diverse HIV-1/2 and SIV primary isolates. J Clin Invest (2012) 1.14
Dominant effector memory characteristics, capacity for dynamic adaptive expansion, and sex bias in the innate Valpha24 NKT cell compartment. Eur J Immunol (2003) 1.13
Enhanced ELISPOT detection of antigen-specific T cell responses from cryopreserved specimens with addition of both IL-7 and IL-15--the Amplispot assay. J Immunol Methods (2002) 1.13
Nucleoside analogue reverse transcriptase inhibitors differentially inhibit human LINE-1 retrotransposition. PLoS One (2008) 1.11
Psoriasis patients are enriched for genetic variants that protect against HIV-1 disease. PLoS Genet (2012) 1.10
Increased expression of intrinsic antiviral genes in HLA-B*57-positive individuals. J Leukoc Biol (2013) 1.09
Timed Gait test: normative data for the assessment of the AIDS dementia complex. J Clin Exp Neuropsychol (2006) 1.09
Inhibition of antigen-specific T cell proliferation and cytokine production by protein kinase A type I. J Immunol (2002) 1.08
Raltegravir cerebrospinal fluid concentrations in HIV-1 infection. PLoS One (2009) 1.08
Cerebrospinal fluid-based kinetic biomarkers of axonal transport in monitoring neurodegeneration. J Clin Invest (2012) 1.05
Effects of cellular activation on anti-HIV-1 restriction factor expression profile in primary cells. J Virol (2013) 1.05
HIV-1 chemokine coreceptor utilization in paired cerebrospinal fluid and plasma samples: a survey of subjects with viremia. J Infect Dis (2005) 1.04
Darunavir concentrations in cerebrospinal fluid and blood in HIV-1-infected individuals. AIDS Res Hum Retroviruses (2009) 1.04
An example of genetically distinct HIV type 1 variants in cerebrospinal fluid and plasma during suppressive therapy. J Infect Dis (2013) 1.03
CD7 is a differentiation marker that identifies multiple CD8 T cell effector subsets. J Immunol (2003) 1.03
HIV-1/HSV-2 co-infected adults in early HIV-1 infection have elevated CD4+ T cell counts. PLoS One (2007) 1.03
Lower cytokine secretion ex vivo by natural killer T cells in HIV-infected individuals is associated with higher CD161 expression. AIDS (2009) 1.03
ELISPOT cell rescue. J Immunol Methods (2004) 1.02
Cerebrospinal fluid signs of neuronal damage after antiretroviral treatment interruption in HIV-1 infection. AIDS Res Ther (2005) 1.02
Identification of human endogenous retrovirus-specific T cell responses in vertically HIV-1-infected subjects. J Virol (2011) 1.01
Vaccination with cancer- and HIV infection-associated endogenous retrotransposable elements is safe and immunogenic. J Immunol (2012) 1.01
Generation of CD3+CD8low thymocytes in the HIV type 1-infected thymus. J Immunol (2002) 1.00
Individuals with pulmonary tuberculosis have lower levels of circulating CD1d-restricted NKT cells. J Infect Dis (2007) 1.00
A comprehensive ex vivo functional analysis of human NKT cells reveals production of MIP1-α and MIP1-β, a lack of IL-17, and a Th1-bias in males. PLoS One (2010) 1.00
Cerebrospinal fluid Alzheimer's biomarker profiles in CNS infections. J Neurol (2012) 0.99
T-cell activation and memory phenotypes in cerebrospinal fluid during HIV infection. J Acquir Immune Defic Syndr (2005) 0.99